Becton, Dickinson and Company (NYSE:BDX – Get Free Report) had its target price hoisted by analysts at Piper Sandler from $275.00 to $280.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical instruments supplier’s stock. Piper Sandler’s price target indicates a potential upside of 13.43% from the company’s previous close.
Other equities research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Evercore ISI increased their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average target price of $283.00.
Get Our Latest Analysis on BDX
Becton, Dickinson and Company Stock Down 0.9 %
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.42 EPS. Equities analysts forecast that Becton, Dickinson and Company will post 14.42 earnings per share for the current fiscal year.
Becton, Dickinson and Company declared that its Board of Directors has authorized a stock repurchase program on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its stock is undervalued.
Insider Activity at Becton, Dickinson and Company
In other news, EVP Roland Goette sold 4,483 shares of the business’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the transaction, the executive vice president now owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of the company’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the transaction, the executive vice president now owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. This represents a 31.61 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is owned by company insiders.
Hedge Funds Weigh In On Becton, Dickinson and Company
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Livelsberger Financial Advisory purchased a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $26,000. Ashton Thomas Securities LLC purchased a new stake in Becton, Dickinson and Company during the third quarter valued at $33,000. Tompkins Financial Corp lifted its position in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the last quarter. Sound Income Strategies LLC grew its stake in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares in the last quarter. Finally, Kennebec Savings Bank bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth about $46,000. 86.97% of the stock is owned by institutional investors.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- Energy and Oil Stocks Explained
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 3 Steel Stocks Soaring After Tariff Announcements
- EV Stocks and How to Profit from Them
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.